- Home
- PLG vs ALDX Comparison
PLG vs ALDX Comparison
Compare PLG & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLG
- ALDX
- Stock Information
- Founded
- PLG 2000
- ALDX 2004
- Country
- PLG Canada
- ALDX United States
- Employees
- PLG N/A
- ALDX N/A
- Industry
- PLG
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- PLG
- ALDX Health Care
- Exchange
- PLG Nasdaq
- ALDX Nasdaq
- Market Cap
- PLG 250.1M
- ALDX 296.0M
- IPO Year
- PLG N/A
- ALDX 2014
- Fundamental
- Price
- PLG $2.06
- ALDX $5.06
- Analyst Decision
- PLG
- ALDX Strong Buy
- Analyst Count
- PLG 0
- ALDX 2
- Target Price
- PLG N/A
- ALDX $9.50
- AVG Volume (30 Days)
- PLG 2.3M
- ALDX 632.6K
- Earning Date
- PLG 11-28-2025
- ALDX 11-05-2025
- Dividend Yield
- PLG N/A
- ALDX N/A
- EPS Growth
- PLG N/A
- ALDX N/A
- EPS
- PLG N/A
- ALDX N/A
- Revenue
- PLG N/A
- ALDX N/A
- Revenue This Year
- PLG N/A
- ALDX N/A
- Revenue Next Year
- PLG N/A
- ALDX $63.48
- P/E Ratio
- PLG N/A
- ALDX N/A
- Revenue Growth
- PLG N/A
- ALDX N/A
- 52 Week Low
- PLG $0.99
- ALDX $1.14
- 52 Week High
- PLG $3.36
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- PLG 43.58
- ALDX 46.91
- Support Level
- PLG $1.85
- ALDX $4.53
- Resistance Level
- PLG $2.26
- ALDX $5.35
- Average True Range (ATR)
- PLG 0.14
- ALDX 0.29
- MACD
- PLG -0.01
- ALDX 0.01
- Stochastic Oscillator
- PLG 34.75
- ALDX 61.82
About PLG Platinum Group Metals Ltd. (Canada)
Platinum Group Metals Ltd is the operator of the Waterberg Project, a bulk underground PGM deposit located in South Africa. Waterberg was discovered by Platinum Group and is being jointly developed with Implats, the Japan Oil, Gas and Metals National Corporation (JOGMEC) and Hanwa Co. Ltd. Waterberg has the potential to be a large-scale, low-cost producer of palladium, platinum, rhodium, and gold. Geographically, it operates in Canada and South Africa.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.